CD4 and myeloid sarcoma: Perhaps most importantly, out of all the drugs studied, ocrelizumab exerted the most consistent and broadest treatment duration effects (Figure 11): The absolute number of recently activated HLA-DR+ CD4+ T cells as well as B cells decreased significantly with the treatment duration, and the proportion of CSF monocytes, normally strongly decreased in untreated MS, increased in the CSF of ocrelizumab-treated patients, positively correlating with treatment duration.